Summarized by Masters of Longevity from PR Newswire.
A news article previewing clinical trial results for a novel oral RIPTAC prostate cancer drug, highlighting early trial activity and future development plans.
Key Takeaways
- JNJ-6143 induced confirmed tumor responses in seventy-five percent of evaluable patients.
- At 50 mg daily, many patients showed large PSA reductions, including near-complete declines.
- Most treatment-related side effects were mild to moderate, supporting further 50 mg study.
